TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10568224
Drug: Alendronate plus
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate plus calcium (10 mg alendronate + 500 mg calcium/day)
Study: 10568224
Drug: Alendronate plus
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alendronate plus calcitriol (0.25 microgram synthetic 1,25‐dihydroxyvitamin D3 + 10 mg alendronate)
Study: 7725591
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of SN + PR
Study: 2183488
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium 75 mg intramuscular (im)
Study: 2183488
Drug: Baralgin 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baralgin 5 mL intravenous (iv)
Study: 23704830
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (routine western medicine)
Study: 26671216
Drug: Robot only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot only (60 minutes of robotic therapy)
Study: 22898992
Drug: Sildenafil (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (100 mg, single dose)
Study: 22898992
Drug: Sodium Nitroprusside
Normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium Nitroprusside (1 ‐ 2 µg/kg/min)
Study: 15611850
Drug: Hypnotherapeutic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypnotherapeutic treatment program (n=10)
Study: 12218617
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 (PGE1) with 60 microg and 100 mg hydrocortisone for 7 days
Study: 12218617
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with 100 mg hydrocortisone
Study: 10624762
Drug: Methacholine challenge
Normalized name: Methacholine Challenge Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methacholine challenge (concentration up to 128 mg x mL(‐1))
Study: 7496872
Drug: Erythromycin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (150 mg/h)
Study: 2044501
Drug: Felbamate (FBM)
Normalized name: Felbamate
DrugBank: Felbamate (DB00949)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Felbamate (FBM) 50 mg/kg per day (maximum 3,000 mg)
Study: 7019201
Drug: Single daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single daily doses of amoxapine
Study: 7019201
Drug: Divided daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divided daily doses of amoxapine
Study: 16464721
Drug: Therapy (specifics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy (specifics not provided)
Study: 21137794
Drug: LF-SQ cream
Normalized name: HYDROXYPROPYL CELLULOSE LF
Approvals — FDA: no, EMA: no, PMDA: no
Description: LF-SQ cream applied twice daily on one half of the face
Study: 21137794
Drug: LF-SQ cream
Normalized name: HYDROXYPROPYL CELLULOSE LF
Approvals — FDA: no, EMA: no, PMDA: no
Description: LF-SQ cream
Study: 21137794
Drug: Placebo (squalane
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (squalane blended cream without fullerene-C60)
Study: 18201449
Drug: Rabeprazole, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole, 20 mg, orally twice daily for 90 days
Study: 15797496
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose pulsed shortwave (10 W)
Study: 15797496
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose pulsed shortwave (20 W)
Study: 12372721
Drug: Systemic adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic adjuvant chemotherapy
Study: 12372721
Drug: Hepatic-artery-based chemotherapy
Normalized name: Sus scrofa artery preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic-artery-based chemotherapy or embolisation
Study: 12372721
Drug: Other therapeutic
Normalized name: Other therapeutic products
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other therapeutic modalities (immunological, radiation, differentiation agents)
Study: 2686455
Drug: Triphasic oral
Normalized name: CeeNU, triphasic oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triphasic oral contraceptives (1) ethinyl estradiol 30, 40, 30 micrograms/day and levonorgestrel 50, 75, 125 micrograms/day; (2) ethinyl estradiol 35 micrograms/day and phased norethindrone 500, 750, 1000 micrograms/day; (3) ethinyl estradiol 35 micrograms/day and norethindrone 500, 1000, 500 micrograms/day
Study: 31734734
Drug: Probiotic product
Normalized name: Rezyst Probiotic Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic product (Lactobacillus plantarum HEAL9 and Lactobacillus paracasei 8700:2) 109 CFU once daily for 3 months
Study: 22319592
Drug: Doxazosin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxazosin (1 mg PO/day, increased every three days by 1 mg up to 4 mg)
Study: 18394742
Drug: Functional retraining
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional retraining programme with daily isokinetic reinforcement of the trunk muscles
Study: 18394742
Drug: Functional retraining
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional retraining programme without daily isokinetic reinforcement of the trunk muscles (Control Group)
Study: 11693896
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (4 mg)
Study: 15607868
Drug: Pamidronate (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate (90 mg)
Study: 11012611
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of pulmonary TB for 6 months
Study: 11012611
Drug: Asthma patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asthma patients (no treatment)
Study: 7678931
Drug: finasteride 1
Normalized name: finasteride 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: finasteride 1 mg/day and finasteride 5 mg/day (combined results)
Study: 21467697
Drug: N-acetylcysteine (NAC,
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC, 705 mg orally before and 12, 24, 36 hours after primary angioplasty)
Study: 21222064
Drug: Pitavastatin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin (2 mg daily)
Study: 15505610
Drug: High-dose cyclophosphamide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cyclophosphamide, carmustine, and thiotepa (CBT) followed by autologous hematopoietic stem cell transplantation (AHST)
Study: 15505610
Drug: High-dose CBT
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose CBT followed by AHST
Study: 1888641
Drug: Cromakalim 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cromakalim 2.0 mg
Study: 1888641
Drug: Cromakalim 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cromakalim 1.0 mg and 2.0 mg
Study: 6669636
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg zopiclone
Study: 23726161
Drug: Inactivated alum-adjuvant
Normalized name: alum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated alum-adjuvant EV71 vaccine
Study: 21897013
Drug: Astaxanthin supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astaxanthin supplementation 1 mg/d for 4 or 12 weeks
Study: 21897013
Drug: Astaxanthin supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astaxanthin supplementation 3 mg/d for 4 or 12 weeks
Study: 15507582
Drug: Combined CBT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined CBT and sertraline
Study: 12102584
Drug: Habit reversal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Habit reversal treatment in a minimal therapist contact (MTC) format
Study: 23629822
Drug: HMG-CoA reductase
Normalized name: HMG-CoA reductase
Approvals — FDA: no, EMA: no, PMDA: no
Description: HMG-CoA reductase inhibitors (statins)
Study: 8129214
Drug: Theo-24 (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theo-24 (800 mg daily)
Study: 8129214
Drug: Theo-Dur (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theo-Dur (800 mg daily)
Study: 1093461
Drug: mini-dose heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: mini-dose heparin
Study: 31327131
Drug: Resveratrol 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol 800 mg/day for 40 days
Study: 28724799
Drug: Galantamine 8
Normalized name: galantamine 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine 8 mg daily for 4 weeks, followed by 16 mg daily for 8 weeks
Study: 25239489
Drug: Continued cognitive-behavior
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continued cognitive-behavior therapy (CBT) for 16 weeks
Study: 25239489
Drug: Sertraline (SRT)
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sertraline (SRT) for 16 weeks
Study: 9411502
Drug: Non-steroid treated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroid treated patients
Study: 9338926
Drug: Steroid treated
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Steroid treated patients
Study: 8450996
Drug: Prednisone (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (0.75 mg/kg/d)
Study: 8450996
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Prednisone 0.3 mg/kg/d and Azathioprine 2.5 mg/kg/d)
Study: 8450996
Drug: Azathioprine (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine (2.5 mg/kg/d)
Study: 27184636
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E 400 mg twice a day (Group A)
Study: 27184636
Drug: UDCA 300
Normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA 300 mg twice a day (Group B)
Study: 12013198
Drug: 20% glycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% glycerin cream
Study: 12013198
Drug: 4% urea
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% urea and 4% sodium chloride cream
Study: 12013198
Drug: cream base
Normalized name: Cream Base
Approvals — FDA: no, EMA: no, PMDA: no
Description: cream base without glycerin (placebo)
Study: 7752049
Drug: Low-dose dobutamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose dobutamine stress echocardiography
Study: 475432
Drug: Rectal paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal paracetamol (15-20 mg/kg)
Study: 475432
Drug: Oral paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral paracetamol (15-20 mg/kg)
Study: 28654682
Drug: Waiting list
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waiting list for therapist-led CBT (treatment as usual)
Study: 25782585
Drug: Upper cervical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Upper cervical manipulative therapy in addition to a multimodal program
Study: 23886091
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (R group)
Study: 17519263
Drug: Morphine PCIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine PCIA (bolus doses for < or =72 h)
Study: 9068509
Drug: Felodipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (10 mg/day)
Study: 11292962
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of alpha tocopherol, rutin, melilotus officinalis, and centella asiatica (oral administration)
Study: 9733230
Drug: 18 g
Normalized name: flotufolastat F 18 gallium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 g fish oil concentrate (6.4 g eicosapentaenoic acid and 3.9 g docosahexaenoic acid)
Study: 9733230
Drug: 18 g
Normalized name: flotufolastat F 18 gallium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18 g placebo
Study: 25012174
Drug: Indomethacin 75
Normalized name: indomethacin 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 75 mg once daily for 6 weeks
Study: 25012174
Drug: Eplerenone 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone 150 mg once daily for 6 weeks
Study: 25012174
Drug: Amiloride 20
Normalized name: amiloride 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride 20 mg once daily for 6 weeks
Study: 12771261
Drug: Intranasal drug
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal drug administration
Study: 12771261
Drug: Intravenous drug
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous drug administration
Study: 10551650
Drug: Neoral 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoral 5 mg/kg BDS
Study: 10551650
Drug: Tacrolimus 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tacrolimus 0.05 mg/kg BDS
Study: 1948126
Drug: rIFN alpha
Normalized name: rIFN-alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rIFN alpha 2b combined with VBMCP chemotherapy
Study: 6832208
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg dose of caffeine as an aqueous oral solution
Study: 6832208
Drug: 5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/kg dose of caffeine as an intravenous infusion
Study: 26302817
Drug: 80 mL
Normalized name: urinary bag 480 mL MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mL double-balloon catheter
Study: 26302817
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL single-balloon catheter
Study: 25015214
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (PK, DLEK, DSEK)
Study: 20600555
Drug: 0.01 mol/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01 mol/L lactic acid immersion for 1 week, 1 month, or 3 months at 37 degrees C or 60 degrees C
Study: 17469693
Drug: Cholinesterase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholinesterase inhibitors (e.g., rivastigmine, donepezil)
Study: 17310311
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CPAP and 100 mg sildenafil on demand for intercourse
Study: 17310311
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CPAP and sildenafil
Study: 9112881
Drug: CO2-enriched water
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO2-enriched water (1200 mg CO2 per kg water; immersion time, twenty minutes)
Study: 1589232
Drug: Naloxone (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (up to 8 mg in 20 ml vehicle)
Study: 25593907
Drug: Extracorporeal photopheresis
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal photopheresis (ECP) administered two consecutive days twice a month
Study: 25593907
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine A (CsA) at a dosage of 3 mg/kg/day
Study: 20562693
Drug: Plasma B-type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma B-type natriuretic peptide and N-terminal fragment of its pro-hormone concentrations
Study: 20562693
Drug: Higher plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher plasma B-type natriuretic peptide and N-terminal fragment of its pro-hormone concentrations
Study: 18557810
Drug: Upper limb
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Upper limb botulinum toxin-A therapy (UL BTX-A)
Study: 12066724
Drug: Dexamethasone 100
Normalized name: Dexamethasone 100 microgram/mL oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 100 mg before induction of anaesthesia (group 1)
Study: 8952856
Drug: urokinase therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: urokinase therapy
Study: 1860787
Drug: Magnesium (Mg)
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium (Mg) pyrrolidone carboxylic acid 360 mg/day
Study: 3533271
Drug: L-5-hydroxytryptophan
Normalized name: L-5-hydroxytryptophan
DrugBank: Oxitriptan (DB02959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-5-hydroxytryptophan
Study: 31679621
Drug: Everolimus-eluting cobalt-chromium
Normalized name: Cobalt
DrugBank: Cobalt (DB14574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus-eluting cobalt-chromium stents (Co-Cr EESs) with 3 months of dual antiplatelet therapy
Study: 25480994
Drug: Xience V
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Xience V drug-eluting stent (DES; n = 48)
Study: 25480994
Drug: Bare-metal stent
Normalized name: menthone 1,2-glycerol ketal, (-)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bare-metal stent (BMS) postdilated with the SeQuent Please drug-eluting balloon (DEB; n = 41)
Study: 22424833
Drug: Intraocular injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraocular injections of bevacizumab every 6 weeks for 6 months
Study: 22424833
Drug: Intraocular injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraocular injections of bevacizumab
Study: 18087554
Drug: Felodipine controlled
Normalized name: Felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Felodipine controlled release tablets with Hydrochlorothiazide
Study: 18087554
Drug: Felodipine controlled
Normalized name: Felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Felodipine controlled release tablets with Metoprolol
Study: 18087554
Drug: Felodipine controlled
Normalized name: Felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Felodipine controlled release tablets with Lisinopril
Study: 18087554
Drug: Felodipine controlled
Normalized name: Felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Felodipine controlled release tablets alone
Study: 18087554
Drug: Felodipine controlled
Normalized name: Felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Felodipine controlled release tablets
Study: 16041734
Drug: Chi‐Ju‐Di‐Huang‐Wan with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chi‐Ju‐Di‐Huang‐Wan with topical eye drops
Study: 16041734
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with topical eye drops
Study: 11981646
Drug: NaCl solutions
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NaCl solutions of different osmolarities (0‐1200 mosmol/l)
Study: 7648940
Drug: Cisapride 5mg
Normalized name: CISAPRIDE 5MG/5ML SUSP,ORAL
DrugBank: Cisapride (DB00604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisapride 5mg three times daily for 4 weeks
Study: 2655526
Drug: Naproxen (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (in addition to amoxicillin)
Study: 2655526
Drug: Placebo (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (in addition to amoxicillin)
Study: 26028962
Drug: Tbo-filgrastim (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tbo-filgrastim (5 μg/kg intravenous infusion)
Study: 26028962
Drug: Moxifloxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin (400 mg oral dose)
Study: 15917194
Drug: Placebo (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intravenous infusion)
Study: 23522488
Drug: 16 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg/m2 sagopilone over 3 h (treatment arm A)
Study: 23522488
Drug: 22 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22 mg/m2 sagopilone over 0.5 h (treatment arm B)
Study: 23522488
Drug: 22 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 22 mg/m2 sagopilone over 3 h (treatment arm C)
Study: 16731406
Drug: Etodolac, 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etodolac, 600 mg, single dose preoperatively and 2 single doses of 600 mg on days 1 and 2 postoperatively
Study: 16731406
Drug: Dexamethasone, 8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone, 8 mg single dose preoperatively and 2 single doses of 4 mg on days 1 and 2 postoperatively
Study: 16285227
Drug: Combined-modality approaches
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined-modality approaches with chemotherapy; specific agents not detailed; duration not specified.
Study: 16285227
Drug: Systemic multiagent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic multiagent chemotherapy for metastatic disease; specific agents not detailed; duration not specified.
Study: 16285227
Drug: Newer cytotoxic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newer cytotoxic drugs and biologically targeted agents; specific agents not detailed; duration not specified.
Study: 9208572
Drug: Parenteral Nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral Nutrition (PN, without glutamine)
Study: 6768376
Drug: Pentazocine 45
Normalized name: Pentazocine
DrugBank: Pentazocine (DB00652)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentazocine 45 mg
Study: 6768376
Drug: Repeated doses
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated doses of pethidine
Study: 6768376
Drug: Pentazocine (more
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentazocine (more than one injection)
Study: 30806186
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy in Bcl-2 negative patients
Study: 30806186
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy in Bcl-2 positive patients
Study: 30806186
Drug: No chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No chemotherapy in Bcl-2 positive patients
Study: 21058480
Drug: Quick meridian
Normalized name: Cal-Quick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quick meridian needling therapy plus scalp acupuncture (group A)
Study: 17542201
Drug: Powered toothbrush
Normalized name: Pro Clean Spinbrush Powered Toothbrush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powered toothbrush (Braun Oral‐B 3D Excel)
Study: 17542201
Drug: Manual toothbrush
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual toothbrush (Oral‐B 35)